ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
  • ABPI Meetings (Adam.ai)
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Facts and figures
  • Global pharmaceutical market
  • Market shares for medicines launched in the previous 5 years

Market shares for medicines launched in the previous 5 years

The relative share of medicines launched in the last 5 years show differences both across the peer group (a sample of other countries within and outside the EU comparable to the UK) and across the years 2009, 2013 and 2017. In this period, all of the OECD countries included in the analysis below increased their relative share for newly launched medicines in 2017.

Although the UK’s market share for products launched in the previous 5 years is the lowest in this group, the share increased in 2017. This is largely explained by launches of significant new classes of medicines, notably new treatments for Hepatitis C, cancer, diabetes and anticoagulation.

The analysis uses list prices and the IMS Midas definition for new products, which is broader than just new molecular entities (NMEs) and, for example, will include branded generics. Where possible new branded generics have been excluded (these will be formulations with significant sales).  The figure for Germany for 2013 has been omitted due to data issues.

Global pharmaceutical market

  • Global health expenditure as a share of GDP
  • Global pharmaceutical expenditure as a share of health expenditure
  • Top 10 pharmaceutical markets by value (USD)
  • Shares of the global pharmaceutical markets
  • Top 10 pharmaceutical markets by value (USD) 2011-2017
  • Market shares for medicines launched in the previous 5 years

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.